Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT

Exclusion Criteria

• •1. History of more than one treatment with SLT in either eye
• •2. Unable or unwilling to discontinue current IOP-lowering medication(s), if applicable
• •3. Prior or current treatment with a rho kinase inhibitor
• •4. Prior microinvasive glaucoma surgery (MIGS)
• •5. Advanced stage of glaucoma, as determined by the investigator based on medical record review
• •6. Any condition that prevents reliable applanation tonometry in either eye (e.g., significant corneal surface abnormalities, scars, keratoconus)
• •7. Previous or currently active corneal disease that, in the opinion of the investigator, could affect the study outcomes
• •8. Active or recurrent intraocular infection, inflammation, iritis or uveitis
• •9. Retinal disease (e.g., diabetic retinopathy, macular degeneration, central retinal vein or artery occlusion, macular edema)
• •10. Intraocular injection performed ≤ 6 months prior to Screening (V1)
• •11. Anticipated use of any topical ocular steroids and/or topical ocular nonsteroidal anti-inflammatory drugs (NSAID) during the study period
• •12. Current participation in any drug or device clinical investigation, receipt of investigational drug within 6 drug half-lives of Screening (V1), or any previous placement of an investigational device.
• •13. Any condition in the opinion of the investigator that would potentially confound the results of this study